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PEET CE estimates for new MS drugs differ greatly depending
upon whether Swedish or Nova Scotia natural history data are
used. As all other factors are held constant, these large CE dif-
ferences are due entirely to differences in rates of disability 
progression.
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OBJECTIVE: The primary objective of the analysis was to simul-
taneously account for and characterize the uncertainty in a cost-
effectiveness model of current triptan (5-HT agonist) therapy for
migraine headache. METHODS: Common components of cost
and effect were identiﬁed as migraine incidence, overall market
share for each triptan, migraine response rate at two hours per
triptan [milligram] strength, migraine recurrence rate per triptan
strength, and the percentage of patients on each triptan strength.
Components speciﬁc to cost alone were the number of migraine
attacks/patient/month and wholesale acquisition cost (WAC) per
triptan strength. Effect was deﬁned as a successfully treated
migraine attack. Costs were determined for every triptan and not
per triptan strength. Uncertainty in the cost-effectiveness ratio
was modeled using Monte Carlo simulation techniques, speciﬁ-
cally utilizing inverse transformation of the component cumula-
tive distribution functions. One thousand random draws were
taken from each of the assumed component distributions, and
cost and effect were computed for each draw. Cost, effect, and
their random components were log-10 transformed, and ordi-
nary least squares regression was performed using cost/effect as
the dependent variable and the components of cost and effect 
as independent variables. Distributional assumptions were logi-
stic-normal for proportional components, Poisson for the
attacks/patient/month component, and uniform for the WAC
component. RESULTS: There was a 10% change in the cost-
effectiveness ratio with a 10% change in attacks/patient/month
and WAC, while the change in the ratio was less than 8% with
a 10% change in the response and recurrence rates. All other
components were insigniﬁcant in their effect. CONCLUSIONS:
The cost-effectiveness model appears to be stable under the
assumptions of its construction, since cost/effect did not change
at a rate greater than the rate of change for any of the signiﬁ-
cant components of cost and effect.
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OBJECTIVES: The purpose of this study was to develop and
apply computer algorithms to an administrative dataset to iden-
tify the prevalence and incidence of epilepsy, and epilepsy-related
mortality within a managed care organization. METHODS: The
study consisted of three phases: exploratory, conﬁrmatory, and
application of the algorithm to estimate prevalence, incidence,
and mortality. Exploratory: Potential epilepsy patients were iden-
tiﬁed based on epilepsy-related codes in administrative data; a
random sample of charts were reviewed to conﬁrm epilepsy
cases. An algorithm was developed utilizing combinations of
epilepsy-related diagnoses, procedures, and medications based
on chart review results. Conﬁrmatory: The algorithm derived in
the exploratory phase was then applied to a new dataset from
the same MCO; a second conﬁrmatory chart review was con-
ducted. Further algorithm reﬁnement was accomplished by
applying logistic regression models to the combined chart review
data from both phases. Application: The ﬁnal models were
applied to 1-, 3-, and 5-year datasets to identify prevalent and
incident cases, which were then linked to a statewide death reg-
istry to derive mortality estimates. RESULTS: The best model
used diagnoses and anti-epileptic drugs as predictors, had a pos-
itive predictive value of 84% (sensitivity, 82%;, speciﬁcity 94%),
and correctly classiﬁed 90% of the cases. Prevalence rates of
7–10/1000 across the 1-, 3-, and 5-year datasets, depending on
age, gender, and ethnicity, were obtained. Annualized incidence
for members continuously enrolled for 3 years was 47/100,000
and 71/100,000 for members continuously enrolled for 5 years.
Crude mortality rates were 2–2.5 times higher for epilepsy
patients identiﬁed with the best model compared to controls.
CONCLUSIONS: The algorithm developed in this project can
be used to monitor trends in incidence, prevalence, and mortal-
ity to inform decisions critical to improving the health care and
overall quality of life for epilepsy patients.
OSTEOPOROSIS
OSTEOPOROSIS—Clinical Outcomes Studies
POS1
THE INFLUENCE OF BONE MINERAL DENSITY TESTING ON
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OBJECTIVE: The inﬂuence of bone mineral density (BMD)
assessment on a woman’s decision to initiate an osteoporosis-
related pharamcotherapy has not been analyzed at the popula-
tion-level through the use of administrative databases. Through
linkage of a BMD database (containing the results of nearly all
BMD measurements performed in the province of Manitoba
since 1990), we measured the inﬂuence of such testing on the
likelihood of initiating an osteoporosis-related pharmacotherapy
(OSRx) in post-menopausal women. METHODS: Hospital,
physician, pharmaceutical, clinical (bone mineral density results)
and demographic data for women continuously residing in 
Manitoba from 1997 through 2002 were obtained from provin-
cial administrative databases. Outcome variable: Initiation of an
OSRx (including hormone replacement therapy [HRT], bispho-
sphonates, selective estrogen receptor modulators[SERM], and
calcitonin). Women with a prescription claim for an OSRx
between 1997–1998 were excluded to restrict the analysis to
incident users. Explanatory variables: BMD test (yes/no), prior
osteoporotic fracture (hip, spine, rib, or vertebral) after age 50,
age, income quintile, and urban vs. rural residence. Likelihood
of initiating an OSRx was analyzed using the Cox proportional
hazards regression. RESULTS: A total of 112,464 women satis-
ﬁed the inclusion criteria, of which, 7.5% received at least one
BMD test and 12.5% (14,031 women) initiated at least one
OSRx within the study period (39.8% HRT; 51.9% bisphos-
phonates; 5.8% SERM; and 2.5% calcitonin). Predictors of
OSRx initiation included (but are not limited to): BMD test in
the previous 6 months (RR 4.05 (95% CL, 3.88–4.22)); and an
osteoporosis-related fracture after age 50 (RR 1.35 (95% CL,
1.29–1.42)). Women with BMD results indicating osteoporosis
at the spine or hip were more likely to initiate an OSRx [RR =
7.72 (95% CL 6.77–8.79) and RR = 6.14 (95% CL 5.44–6.92)
spine & hip, respectively]. CONCLUSIONS: Receipt of a BMD
assessment increases the likelihood a woman will initiate an
